Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

JUBILANT LIFE SCIENCES LIMITED - 530019 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Sub.: Publication of information regarding 42nd Annual General Meeting of the Company to be held on Friday, September 11, 2020 through Video Conferencing/ Other Audio Visual Means This is to inform you that the 42nd Annual General Meeting ('AGM') of the Company is scheduled to be held on Friday, September 11, 2020 at 10:00 A.M. (1ST) through Video Conferencing/ Other Audio Visual Means. The Notice of the 42nd AGM of the Company and the Annual Report for the financial year 2019-20 will be sent to all the shareholders whose email addresses are registered with the Company/ Depository Participants and will also be available on the Company''s website at www.jubl.com in due course. We enclose herewith copies of the advertisements published on August 15, 2020, in MINT (English) and HINDUSTAN (Hindi) pursuant to General Circular No. 20/2020 dated May 5, 2020 issued by the Ministry of Corporate Affairs. This is for information and record.
15-08-2020
Bigul

JUBILANT LIFE SCIENCES LIMITED - 530019 - Board Meeting Intimation for Intimation Of Board Meeting - September 4, 2020

 JUBILANT LIFE SCIENCES LIMITEDhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/09/2020 ,inter alia, to consider and approve In terms of Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Friday, September 4, 2020, to inter-alia consider Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2020. This is for information and record.
14-08-2020
Bigul

JUBILANT LIFE SCIENCES LIMITED - 530019 - Disclosure of Voting results of Court Convened Meeting (Regulation 44(3) of SEBI (LODR) Regulations, 2015)

 Jubilant Life Sciences Ltd has informed BSE regarding the details of Voting results of Court Convened Meeting, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here
10-08-2020
Bigul

JUBILANT LIFE SCIENCES LIMITED - 530019 - Outcome Of National Company Law Tribunal Convened Meetings Of The Equity Shareholders, Secured Creditors And Unsecured Creditors

 In continuation to our letters dated July 3, 2020, we wish to inform you that meetings of the Equity Shareholders, Secured Creditors and Unsecured Creditors of the Company were convened at the Registered Office of the Company at Bhartiagram, Gajraula, District Amroha-244223, Uttar Pradesh on Saturday, August 8, 2020 at 11:00 A.M, 2:00 P.M. and 3:30 P.M. respectively, to approve the Composite Scheme of Arrangement. Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit the following: a) Summary of the proceedings of the NCLT convened meeting of the Equity Shareholders. b) Scrutinizer''s Report dated August 8, 2020 of the Equity Shareholders, Secured Creditors and Unsecured Creditors meetings. This is for your information and records.
09-08-2020
Bigul

Jubilant Life Sciences presents 1,000 vials of Remdesivir to UP CM Yogi Adityanath

 The drug is being made available to over 1,000 hospitals providing COVID-19 treatment in India through the company's distribution network, Jubilant Life Sciences said in a statement
08-08-2020
Bigul

Jubilant Life slips 2.5% after scaling a 52-week peak in early trade

 The company said it has launched the generic version of antiviral drug remdesivir in India.
04-08-2020
Bigul

JUBILANT LIFE SCIENCES LIMITED - 530019 - Launch Of 'JUBI-R' (Remdesivir) In India For The Treatment Of COVID-19

 We refer to our letter dated July 20, 2020 intimating about approval of 'JUBI-R' (remdesivir). We enclose a communication pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 pertaining to launch of 'JUBI-R' (remdesivir) in India for the treatment of COVID-19. We request you to take the same on record.
03-08-2020

Jubilant Life Sciences gets DCGI nod for generic version of COVID-19 drug

 The company's subsidiary Jubilant Generics has received the approval from Drug Controller General of India (DCGI) to manufacture and market investigational drug remdesivir 100 mg/vial (lyophilized injection), Jubilant Life Sciences said in a late night filing to BSE.
21-07-2020
Bigul

JUBILANT LIFE SCIENCES LIMITED - 530019 - Approval Of 'JUBI-R' (Remdesivir) In India For The Treatment Of COVID-19

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose a communication pertaining to approval of 'JUBI-R' (remdesivir) in India for the treatment of COVID-19. We request you to take the same on record.
20-07-2020
Bigul

JUBILANT LIFE SCIENCES LIMITED - 530019 - Shareholding for the Period Ended June 30, 2020

 Jubilant Life Sciences Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2020. For more details, kindly Click here
20-07-2020
Next Page
Close

Let's Open Free Demat Account